Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

Luger SM, Ringdén O, Zhang MJ, Pérez WS, Bishop MR, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale RP, Giralt SA, Gulbas Z, Gupta V, Hale GA, Lazarus HM, Lewis VA, Lill MC, McCarthy PL, Weisdorf DJ, Pulsipher MA.

Bone Marrow Transplant. 2012 Feb;47(2):203-11. doi: 10.1038/bmt.2011.69. Epub 2011 Mar 28.

2.

Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Abdul Wahid SF, Ismail NA, Mohd-Idris MR, Jamaluddin FW, Tumian N, Sze-Wei EY, Muhammad N, Nai ML.

Stem Cells Dev. 2014 Nov 1;23(21):2535-52. doi: 10.1089/scd.2014.0123. Epub 2014 Sep 17. Review.

3.

Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Pingali SR, Champlin RE.

Bone Marrow Transplant. 2015 Sep;50(9):1157-67. doi: 10.1038/bmt.2015.61. Epub 2015 May 18. Review.

4.
5.

The evolution of hematopoietic SCT in myelodysplastic syndrome.

Kindwall-Keller T, Isola LM.

Bone Marrow Transplant. 2009 Apr;43(8):597-609. doi: 10.1038/bmt.2009.28. Epub 2009 Mar 2. Review.

PMID:
19252532
6.

Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.

Shimoni A, Nagler A.

Best Pract Res Clin Haematol. 2011 Sep;24(3):369-79. doi: 10.1016/j.beha.2011.05.002. Epub 2011 Jun 24. Review.

PMID:
21925090
7.

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.

Hamadani M, Mohty M, Kharfan-Dabaja MA.

Cancer Control. 2011 Oct;18(4):237-45. Review.

8.

Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.

Blaise D, Vey N, Faucher C, Mohty M.

Haematologica. 2007 Apr;92(4):533-41. Review.

9.

Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.

Servais S, Baron F, Beguin Y.

Transfus Apher Sci. 2011 Apr;44(2):205-10. doi: 10.1016/j.transci.2011.01.019. Epub 2011 Feb 22. Review.

11.
12.

Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia.

Goyal G, Gundabolu K, Vallabhajosyula S, Silberstein PT, Bhatt VR.

Ther Adv Hematol. 2016 Jun;7(3):131-41. doi: 10.1177/2040620716643493. Epub 2016 Apr 22. Review.

13.

Reduced-intensity conditioning transplantation in myeloid malignancies.

Storb R.

Curr Opin Oncol. 2009 Jun;21 Suppl 1:S3-5. doi: 10.1097/01.cco.0000357467.45843.ba. Review.

14.

Reduced-intensity conditioned allogeneic SCT in adults with AML.

Reshef R, Porter DL.

Bone Marrow Transplant. 2015 Jun;50(6):759-69. doi: 10.1038/bmt.2015.7. Epub 2015 Mar 2. Review.

PMID:
25730186
15.

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.

Atilla E, Ataca Atilla P, Demirer T.

Balkan Med J. 2017 Jan;34(1):1-9. doi: 10.4274/balkanmedj.2017.0055. Epub 2017 Jan 5. Review.

16.

What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?

Appelbaum FR.

Best Pract Res Clin Haematol. 2008 Dec;21(4):667-75. doi: 10.1016/j.beha.2008.06.005. Review.

17.

Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?

Marcondes M, Deeg HJ.

Best Pract Res Clin Haematol. 2008 Mar;21(1):67-77. doi: 10.1016/j.beha.2007.11.005. Review.

18.

Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.

Sorror ML, Appelbaum FR.

Expert Rev Hematol. 2013 Oct;6(5):547-62. doi: 10.1586/17474086.2013.827418. Epub 2013 Oct 2. Review.

19.

Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens.

Saber W, Horowitz MM.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):478-484. Review.

PMID:
27913519
20.

Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis.

Vaxman I, Ram R, Gafter-Gvili A, Vidal L, Yeshurun M, Lahav M, Shpilberg O.

Bone Marrow Transplant. 2015 May;50(5):706-14. doi: 10.1038/bmt.2014.325. Epub 2015 Feb 9. Review.

PMID:
25665042

Supplemental Content

Support Center